Glucosamine, as a bone health care popular product that has been on the market for many years in developed countries, is rarely known in China. This market is bred with vitality.
International: The main force of bone and joint health products
Glucosamine has three main functions: first, to repair (or repair) articular cartilage and its surrounding soft tissue that has worn out, to keep the articular surface smooth; second, to promote more synovial fluid between joints, thereby reducing walking The friction between the joints; third, anti-inflammatory effect, can eliminate arthritis symptoms.
Under the support of a large number of studies, the health care and therapeutic effects of glucosamine on bones and joints were recognized by the medical professions of the United States, Europe, and Japan in the 1990s, and they were successively approved for listing as health products. So far, products that add glucosamine to the bone-joint health foods marketed in countries around the world have occupied half of the country's total.
The United States is the first country in the world to promote the production and application of glucosamine bone and joint health foods. Due to the large number of people suffering from bone and joint diseases, many American elderly people take glucosamine products all year long.
In the U.S. market, glucosamine bone and joint products can be roughly divided into two categories: First, glucosamine preparations added with chemical anti-inflammatory drugs are under the strict management of the FDA. Such preparations are mainly glucosamine + ibuprofen, glucosamine + piroxicam. The second is a large number of glucosamine health food products, which are managed as dietary supplement products.
Among them, glucosamine health food can be divided into three categories: First, a simple glucosamine composition; Second, glucosamine + chondroitin sulfate composite preparation; Third, glucosamine + other components of the compound products, such as glucosamine +MSM (a health-protective substance for protecting bone and joints), glucosamine + bromelain, glucosamine + vitamin D3, glucosamine + hyaluronic acid, etc.
The US bone and joint health food products have annual sales of 900 million to 1 billion US dollars. Among them, the annual growth rate of glucosamine products is as high as 36%, and 90% of raw materials come from China.
China: Raw materials, niche consumption
Since the 1970s, China has made use of a large number of by-products of marine aquaculture processing in coastal areas, namely shrimp and crab shells to produce chitin, and has developed a series of derivative products such as chitosan and glucosamine. In the mid-1990s, China had become the largest producer and exporter of chitin and glucosamine in the world.
At present, in the coastal areas of China, at least one or twenty companies are producing glucosamine raw materials, with the highest annual output in Zhejiang and Jiangsu, followed by Shandong and Liaoning. The total domestic production capacity of glucosamine is 2800-3000 tons, and the actual output is about 1,500 tons. The annual consumption of glucosamine raw materials in the international market is around 3,000 tons.
However, the health effects of glucosamine are not well known in China, and its presence on the domestic health care products market is rare. A large amount of raw materials are exported to Europe, America and Japan at a low price.
In recent years, glucosamine bone health foods (such as McKinley, O'Dili, etc.) produced by overseas companies have begun to enter the Chinese market, but the price is high. Each bottle (300 capsules) costs 300 to 400 yuan (at In the United States, the price of each bottle is only more than 20 US dollars, and the selling price greatly exceeds the economic affordability of the average consumer in China.
However, many domestic companies have started to produce domestic glucosamine-based health foods, and glucosamine-based health foods have been marketed in Shandong, Zhejiang, Xiamen, Dalian, Qingdao, Guangzhou and Beijing. Jiangsu Nantong Shuanglin Biology Co., Ltd. (one of the largest enterprises with the largest sales and sales of chitin in China) is also preparing to market glucosamine health products.
At present, there are 130 million elderly people over the age of 60 in China, among which at least 40% suffer from bone diseases of varying degrees. As a bone health product that has been marketed in developed countries for many years, glucosamine will undoubtedly have good development prospects in the country and is expected to be sold annually. The peak can reach 5 billion to 6 billion yuan. The key to the current impact on the market lies in the retail price, which depends on whether domestic glucosamine health foods can be lowered, making it a popular consumer product.